New Strong Buy Stocks for November 15th

Shares of Domino’s Pizza, Inc. rose sharply in today's pre-market trading after a 13F filing showed that Berkshire Hathaway added a new stake.

Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino's Pizza.

Domino’s Pizza shares jumped 7.8% to $470.00 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers

• The Arena Group Holdings, Inc. gained 233.3% to $1.90 in pre-market trading after it announced its first ever profitable quarter.
• Greenidge Generation Holdings Inc. rose 49.8% to $3.70 in pre-market trading. Greenidge said New York Supreme Court Judge rejected Department of Environmental Conservation’s action to deny its application for renewal of Title V Air Permit.
• Innovation Beverage Group Limited I gained 35.2% to $1.46 in pre-market trading after gaining 40% on Thursday.
• Beneficient gained 29.6% to $1.62 in pre-market trading after the company reported a year-over-year increase in second-quarter revenue results.
• Siyata Mobile Inc. gained 26.6% to $1.62 in pre-market trading following third-quarter results.
• TCTM Kids IT Education Inc. gained 23.1% to $0.99 in pre-market trading after dipping 12% on Thursday.
• Red Cat Holdings, Inc. climbed 19.4% to $4.80 in pre-market trading after jumping more than 5% on Thursday.
• Despegar.com, Corp. gained 12.8% to $16.77 in pre-market trading after the company reported better-than-expected third-quarter financial results.
• Jet.AI Inc. J gained 9.8% to $6.37 in pre-market trading after dipping more than 28% on Thursday.

Losers

• TFF Pharmaceuticals, Inc. shares tumbled 69.7% to $0.4890 in pre-market trading after the company announced it will wind down its operations.
• Quantum Computing Inc. shares fell 25.5% to $3.28 in pre-market trading after the company reported a registered direct offering of $40 million priced at-the-market under Nasdaq rules.
• Expion360 Inc X shares fell 22.3% to $2.68 in pre-market trading after the company reported a year-over-year decline in third-quarter revenue results.
• Digital Brands Group, Inc. declined 21.8% to $0.1060 in pre-market trading after the company reported worse-than-expected third-quarter EPS results and a year-over-year decline in revenue.
• Tivic Health Systems Inc dipped 15.9% to $0.31 in pre-market trading after the company reported a year-over-year decline in third-quarter sales results.
• CERo Therapeutics Holdings Inc shares dipped 14.7% to $0.16 in pre-market trading after falling around 12% on Thursday.
• AST SpaceMobile, Inc. fell 13.8% to $23.10 in pre-market trading after the company reported worse-than-expected quarterly financial results.
• Carmell Corp fell 13.1% to $0.24 in pre-market trading after posting third-quarter results.
• Oklo Inc. fell 7.8% to $22.00 in pre-market trading following third-quarter results.
• Applied Materials, Inc. fell 7.3% to $172.55 in today's pre-market trading following first-quarter results.

Now Read This:

• Jim Cramer Recommends Microsoft, Praises American Water Works For Being ‘Consistent’

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

AST SpaceMobile Inc reported financial results for the third quarter Thursday after the bell. Here’s a look at the key details from the report.

Q3 Earnings: AST SpaceMobile reported third-quarter revenue of $1.1 million. The company reported an adjusted loss of $1.10 per share, missing analyst estimates for a loss of 20 cents per share, according to Benzinga Pro.

Operating expenses for the third quarter totaled $66.6 million, up $2.7 million from the second quarter. The company ended the period with $518.9 million in cash, cash equivalents and restricted cash.

“We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,” said Abel Avellan, founder, chairman and CEO of AST SpaceMobile.

“With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We’ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.”

AST SpaceMobile executives will hold a conference call at 5 p.m. ET to further discuss the quarter with investors.

See Also: Rocket Lab CEO Touts SpaceX Rival Status, Trump Impact On Space As Stock Surges Almost 30%

Service Agreements: AST SpaceMobile separately announced launch services agreements securing the orbital launch capacity to enable continuous space-based cellular broadband service coverage.

The company’s global service will initially target key markets including the U.S., Europe, Japan and other strategic markets.

The company’s next-gen Block 2 Bluebird satellites are expected to deliver up to 10 times the bandwidth capacity of the Bluebirds currently in orbit, and are designed to be compatible with all major launch vehicles.

“With these new launch services agreements, our in-house vertically integrated manufacturing capabilities in Texas, our mobile operator partners, and the additional capital raised during 2024, we are now well-positioned to reach our goal of continuous cellular broadband service coverage, enabling our service to hundreds of millions of users around the world and the U.S. government,” said Scott Wisniewski, president of AST SpaceMobile.

ASTS Price Action: AST SpaceMobile shares were down 13.47% after hours, trading at $23.19 at the time of publication Thursday, according to Benzinga Pro.

Photo: Courtesy of AST SpaceMobile.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

AST SpaceMobile, Inc. (ASTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 155.56%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.14, delivering a surprise of 26.32%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

AST SpaceMobile, which belongs to the Zacks Wireless Equipment industry, posted revenues of $1.1 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 50%. This compares to zero revenues a year ago.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

AST SpaceMobile shares have added about 362.5% since the beginning of the year versus the S&P 500's gain of 25.5%.

What's Next for AST SpaceMobile?

While AST SpaceMobile has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for AST SpaceMobile: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $4.2 million in revenues for the coming quarter and -$0.97 on $7.8 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Wireless Equipment is currently in the bottom 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Computer and Technology sector, C3.ai, Inc. (AI), has yet to report results for the quarter ended October 2024. The results are expected to be released on December 9.

This company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of -23.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

C3.ai, Inc.'s revenues are expected to be $91.01 million, up 24.3% from the year-ago quarter.

Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -18.52%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.33, delivering a surprise of 5.71%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Spero Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $13.47 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 41.44%. This compares to year-ago revenues of $25.47 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Spero Therapeutics shares have lost about 10.9% since the beginning of the year versus the S&P 500's gain of 25.5%.

What's Next for Spero Therapeutics?

While Spero Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Spero Therapeutics: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.21 on $9 million in revenues for the coming quarter and -$1.38 on $51.5 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Phreesia (PHR), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended October 2024. The results are expected to be released on December 9.

This developer of health care software is expected to post quarterly loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Phreesia's revenues are expected to be $106 million, up 15.7% from the year-ago quarter.

Zacks Investment Research